medigraphic.com
ISSN 0188-9796 (Print)

2002, Number 4

<< Back

Rev Endocrinol Nutr 2002; 10 (4)

The Unit Research in Clinical Epidemiology of the Hospital de Especialidades Centro Médico “La Raza”, IMSS, México, D.F: History and significance at 4 years of its foundation

Vadillo BM

Language: Spanish
References: 10
Page: 209-212
PDF size: 59.98 Kb.


Text Extraction

No abstract


REFERENCES

  1. Maksymovych WP, Aviña ZJA, Luong MH, Russell AS. An open study of pentoxifyline in the treatment of severe refractory rheumatoid arthritis. J Rheumatol 1995; 22: 625-629.

  2. Aviña ZJA, Galindo RG, Davis P, Russell AS. Sensitivity, specificity and predictive values among ELISA kits in the detection of anti-dsDNA antibodies. Lupus 1995; 4: 370-374.

  3. Galindo RG, Aviña ZJA, Pizarro S, Diaz LV, Saucedo N, Fuentes M, Lavalle C. Efficacy of cyclophosphamide pulse therapy in optic neuritis secondary to systemic lupus erythematosus. An open trial. Am J Med 1999; 106: 65-69.

  4. Jara QLJ, Graef A, Lavalle C. Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus. J Rheumatol 1991; 18: 349-353.

  5. Jara LJ, Lavalle C, Fraga A, Silveira L, Martinez OP, Germain G, Espinoza RL. Prolactin, immunoregulation and autoimmune diseases. Semin Arthritis Rheum 1991; 20: 273-284.

  6. Jara LJ, Silviera LH, Cuellar ML, Pineda CJ, Scopelitis E, Espinoza RL. Hyperprolactinemia in Reiter’s syndrome. J Rheumatol 1994; 21: 1292-1297.

  7. Jara LJ, Irigoyen L, Ortiz MJ, Zazueta B, Bravo G, Espinoza RL. Prolactin an interleukin-6 (IL-6) in neuropsychiatric lupus erythematosus. Clin Rheumatol 1998; 17: 110-114.

  8. Berumen J, Miranda E, Zafra G, Casas L, Segura E, Ordoñez RM, Aguirre J, Martínez M, Rosas A, Ibarra V, Pedraza L, Saad A, Marroquín A, Gutierrez M, Martínez A, Gariglio P. Epidemiología molecular de cánceres de alta incidencia en México. Gac Med Mex 1997; 133; S1: 35-43.

  9. Jungwirth A, Schally AV, Pinsky J, Vadillo-Buenfil-M. Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. Brit J Cancer 1997; 75: 1585-1592.

  10. Halmos G, Schally AV, Pinsky J, Vadillo-Buenfil-M, Groot K. Down regulation of pituitary receptors for luteinizing-hormone releasing hormone (LHRH) antagonist Cetrorelix. Proc Natl Acad Sci USA 1996; 93: 2398-2402.




2020     |     www.medigraphic.com